Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carcinoma. Merus' other bispecific antibody, zenocutuzumab, has a high chance of approval for NRG1-positive NSCLC and pancreatic cancer, with a decision expected later in 2024.

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Merus stock catapulted to a record high Friday after its experimental regimen for head-and-neck cancer beat expectations in a key study.

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

-   60% response rate observed among 10 evaluable patients -   F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed -   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody. This designation follows receipt of Fast Track Designation for petosemtamab for the treatment of patients with recurrent or metastatic HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death protein 1 (anti-PD-1) antibody announced in August 2023.

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

If approved, Zeno will be the first targeted therapy for NRG1+ cancer If approved, Zeno will be the first targeted therapy for NRG1+ cancer

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Merus N.V. (MRUS) Report Negative Q1 Earnings?

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Gilead Sciences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus' proprietary Triclonics® platform along with Gilead's oncology expertise to research and develop multiple, separate preclinical research programs. Merus is a clinical-stage onco.

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Merus N.V. results from the phase 1/2 eNRGy trial, using zenocutuzumab for the treatment of patients with NRG1+ PDAC and NSCLC, are expected in the 1st half of 2024. Should results from the phase 1/2 eNRGy trial turn out to be positive, then Merus will be able to file BLA of zenocutuzumab for the treatment of patients NRG1+cancers. Petosemtamab is another clinical candidate being advanced in the pipeline for the treatment of both 1st-line and 2nd-line HNSCC; Data for each program targeting such populations is expected in 2024.

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:

Merus to Participate in Upcoming Investor Conferences

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?

The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, showed promising results in a phase 1/2 trial for head and neck cancer, with an objective response rate of 35.7%. Zenocutuzumab, targeting HER2/HER3 in NRG1-positive NSCLC and pancreatic cancer, demonstrated an overall response rate of 37.2% and 42.4%.

Merus: (Maybe) Building A Better Bispecific

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock.

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet

Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

The average of price targets set by Wall Street analysts indicates a potential upside of 85.4% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

The consensus price target hints at an 83.3% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet

– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024

News for Merus Stock (MRUS)